Proteomics and transcriptomics approaches are identifying gene expression changes and protein modifications induced by BPC-157 treatment, providing molecular signatures of peptide action
10.1016/S0140-6736(85)91481-3
As patents expire and potential generic or biosimilar versions emerge (e.g., generic liraglutide by Teva in 2024 ( [68] )), costs might come down, but for newer agents like semaglutide or tirzepatide, it could be years
Lu Y, Sareddy GR, Wang J, Wang R, Li Y, Dong Y, et al
The FDA must remain vigilant and take robust measures to eliminate these practices. Counterfeit medications were the foremost concern of the National Association of Attorneys General in its Feb
High B12 is a marker, not a cause